Nrx Pharmaceuticals Inc Stock Price, News & Analysis

NRx Pharmaceuticals (NASDAQ:NRXP) will release its third quarter 2025 financial results before the market opens on Monday, November 17, 2025.

The company will host a conference call and corporate/financial update on November 17, 2025 at 8:30 AM ET, with a live webcast available at https://ir.nrxpharma.com/events and the press release posted at https://ir.nrxpharma.com/. Participants can join by phone domestically at 1-800-717-1738 or internationally at +1-646-307-1865.

HOPE Therapeutics (NASDAQ: NRXP) began offering the Ampa ONE-D protocol for treatment‑resistant depression in Florida on Nov 10, 2025, deploying the FDA‑cleared Ampa device at clinics in Sarasota, Naples and Fort Myers with six Florida locations planned by year‑end 2025.

The ONE‑D protocol reports 87% response and 72% remission at 6 weeks in nonrandomized results when single‑day TMS is combined with physician‑prescribed D‑cycloserine and lisdexamfetamine; D‑cycloserine is also a component of investigational NRX‑101, which has Breakthrough Therapy designation and expanded access availability.

HOPE Therapeutics (NASDAQ: NRXP) announced a strategic acquisition of a stake in Cohen and Associates, LLC and the addition of Rebecca Cohen, MD as HOPE Medical Director on October 20, 2025. Cohen and Associates brings over a decade of interventional psychiatry and TMS expertise and offers ketamine, TMS, and medication management for suicidal depression, PTSD and other CNS disorders.

The company said the deal enables immediate expansion in Western Florida and Palm Beach and is expected to be accretive to HOPE Therapeutics revenue and EBITDA, while Dr. Cohen will oversee medical standards across HOPE’s Florida locations.

NRx Pharmaceuticals (NASDAQ: NRXP) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 at 9:30 AM ET. CEO Jonathan Javitt will give a corporate update covering the company's plan to launch a low-dose D-Cycloserine (DCS) product intended to boost Transcranial Magnetic Stimulation (TMS) effectiveness for depression, citing recent medical evidence.

The presentation will detail NRx's newly acquired clinical operations in Florida and ongoing collaboration with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD. A live webcast is available to registered attendees and a replay will be posted under the company’s Events page.

NRx Pharmaceuticals (NASDAQ:NRXP) has re-filed an Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine formulation, following FDA's approval of its Suitability Petition. The product aims to address the current $750 million ketamine market, projected to reach $3.35 billion globally by 2034.

KETAFREE™ eliminates benzethonium chloride (BZT), a known neurotoxic preservative, and represents a strategic reshoring of drug manufacturing to the US amid current ketamine shortages. The company has filed a citizen's petition to remove BZT from all IV ketamine presentations and has demonstrated long-term stability with its patented preservative-free formulation, manufactured in partnership with Nephron Pharmaceuticals.

This ANDA filing is separate from NRx's ongoing NDA submission for NRX-100 in suicidal ideation treatment, which recently received FDA Fast Track designation.

NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its Suitability Petition regarding KETAFREE™, a preservative-free ketamine product. This approval enables the company to refile its Abbreviated New Drug Application (ANDA) for a single-patient dose formulation that eliminates the toxic preservative Benzethonium Chloride found in current multi-dose vials.

The development aligns with two key administrative policy objectives: reshoring strategically important sterile drugs and removing toxic preservatives from medications. The current ketamine market is valued at $750 million. Beyond KETAFREE™, NRx aims to develop NRX-100, a non-generic ketamine formulation for treating suicidal depression and PTSD under a New Drug Application.

NRx Pharmaceuticals (NASDAQ:NRXP) has completed the acquisition of Dura Medical through its subsidiary HOPE Therapeutics. Dura Medical, along with pending acquisitions of Neurospa TMS and Cohen & Associates, will establish a network of over 8 locations along Florida's West Coast providing interventional psychiatry services.

Dura Medical, founded in 2018 and currently operating in Naples and Ft. Myers, offers comprehensive treatment for depression, PTSD, and chronic pain through advanced procedures including Ketamine Therapy, TMS, Spravato, and Stellate Ganglion Blocks. The company is revenue-generating and EBITDA positive.

Stephen Durand, a US Army Veteran and Dura's founder, will serve as Director of Florida Clinic Operations. The company aims to treat over 10,000 people by 2026 and participates in the Veterans Affairs Community Cares Network to support military veterans.

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, announced their participation in H.C. Wainwright's 27th Annual Global Investment Conference.

The company's Chairman and CEO, Dr. Jonathan Javitt, will engage in a fireside chat on September 8, 2025, from 4:30 to 5:00 PM ET. The presentation will be available via webcast on the company's investor relations website, with a replay accessible for 30 days after the event.

Management will also be conducting one-on-one meetings with investors during the conference.

NRx Pharmaceuticals (NASDAQ:NRXP) presented at the Global Passion Project symposium, sponsored by Rockefeller Global Family Office, detailing plans for the launch of HOPE Therapeutics clinics in Fall 2025. The company announced Matthew Rockefeller is joining HOPE Therapeutics' Advisory Board.

HOPE Therapeutics will establish a flagship location in Palm Beach, FL, offering a unique one-week residential program combining multiple treatments including ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy to treat suicidal depression, PTSD, and cognitive dysfunction. The company aims for a 90% response rate through this combined treatment approach.

NRx recently secured $8.8 million in funding from biotech investors through a common stock offering with no warrants or variable rate features.